Stock listing
NASDAQ:AURA Aura Biosciences, Inc. Stock
Home listing (NASDAQ) of Aura Biosciences, Inc.
Follow Aura Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AURA
$6.87 USD -0.27 (-3.8%)
Close on Nov 20, 2026
- Day range
- $6.51 – $6.98 USDNov 20, 2026
- Volume
- 791,133 sharesNov 20, 2026
- Market cap
- $715.0M USDAt the close on Nov 20, 2026 · price × 104.1M shares outstanding
- 52-week range
- $4.73 – $9.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.64M USDMedian day 762,494 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AURA · Home | $6.87 USD | -0.27 (-3.8%) | 791,133 | $6.505 | $6.975 | $6.505 | $7.14 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AURA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.87 | -0.27 | -3.8% | $6.505 | $6.975 | $6.505 | 791,133 | |
| $7.14 | -0.01 | -0.1% | $7.17 | $7.24 | $7.00 | 687,840 | |
| $7.15 | -0.07 | -1.0% | $7.20 | $7.305 | $7.00 | 627,640 | |
| $7.22 | +0.11 | +1.5% | $7.05 | $7.29 | $6.95 | 779,116 | |
| $7.11 | 0.00 | 0.0% | $7.24 | $7.24 | $6.865 | 610,303 | |
| $7.11 | -0.50 | -6.6% | $7.53 | $7.53 | $7.06 | 1,006,708 | |
| $7.61 | -0.04 | -0.5% | $7.71 | $7.715 | $7.31 | 648,547 | |
| $7.65 | -0.01 | -0.1% | $7.65 | $7.945 | $7.42 | 875,183 | |
| $7.66 | +1.10 | +16.8% | $6.67 | $7.70 | $6.62 | 1,128,663 | |
| $6.56 | +0.22 | +3.5% | $6.35 | $6.66 | $6.17 | 859,019 | |
| $6.34 | -0.31 | -4.7% | $6.55 | $6.63 | $6.27 | 790,866 | |
| $6.65 | +0.41 | +6.6% | $6.42 | $6.66 | $6.255 | 1,001,928 | |
| $6.24 | +0.21 | +3.5% | $6.07 | $6.325 | $6.045 | 643,057 | |
| $6.03 | -0.11 | -1.8% | $6.13 | $6.16 | $5.88 | 746,584 | |
| $6.14 | -0.155 | -2.5% | $6.30 | $6.43 | $6.03 | 533,013 | |
| $6.295 | -0.105 | -1.6% | $6.46 | $6.51 | $6.26 | 769,975 | |
| $6.40 | +0.10 | +1.6% | $6.27 | $6.41 | $6.21 | 541,882 | |
| $6.30 | +0.12 | +1.9% | $6.20 | $6.31 | $6.095 | 680,261 | |
| $6.18 | -0.12 | -1.9% | $6.31 | $6.42 | $6.145 | 907,585 | |
| $6.30 | -0.16 | -2.5% | $6.33 | $6.40 | $6.16 | 722,144 | |
| $6.46 | 0.00 | 0.0% | $6.46 | $6.59 | $6.35 | 955,317 | |
| $6.46 | -0.10 | -1.5% | $6.46 | $6.61 | $6.385 | 933,595 | |
| $6.56 | +0.27 | +4.3% | $6.32 | $6.77 | $6.18 | 1,164,028 | |
| $6.29 | +0.19 | +3.1% | $6.13 | $6.37 | $6.12 | 556,794 | |
| $6.10 | -0.24 | -3.8% | $6.31 | $6.355 | $6.095 | 762,494 | |
| $6.34 | +0.17 | +2.8% | $6.23 | $6.415 | $6.17 | 604,522 | |
| $6.17 | -0.10 | -1.6% | $6.21 | $6.28 | $6.085 | 1,009,778 | |
| $6.27 | -0.27 | -4.1% | $6.53 | $6.56 | $6.18 | 1,663,238 | |
| $6.54 | 0.00 | 0.0% | $6.55 | $6.70 | $6.50 | 613,137 | |
| $6.54 | +0.035 | +0.5% | $6.48 | $6.70 | $6.46 | 962,557 | |
| $6.505 | +0.045 | +0.7% | $6.41 | $6.61 | $6.36 | 1,692,188 | |
| $6.46 | +0.29 | +4.7% | $6.10 | $6.563 | $6.10 | 723,720 | |
| $6.17 | -0.05 | -0.8% | $6.26 | $6.27 | $6.10 | 607,526 | |
| $6.22 | +0.13 | +2.1% | $6.09 | $6.42 | $6.05 | 589,813 | |
| $6.09 | +0.05 | +0.8% | $6.11 | $6.15 | $5.97 | 2,099,065 | |
| $6.04 | -0.24 | -3.8% | $6.36 | $6.36 | $6.00 | 807,346 | |
| $6.28 | +0.13 | +2.1% | $6.21 | $6.36 | $6.12 | 677,458 | |
| $6.15 | 0.00 | 0.0% | $6.13 | $6.175 | $6.04 | 795,446 | |
| $6.15 | +0.15 | +2.5% | $6.03 | $6.17 | $6.00 | 483,657 | |
| $6.00 | -0.15 | -2.4% | $6.18 | $6.18 | $5.985 | 1,116,505 | |
| $6.15 | +0.13 | +2.2% | $6.01 | $6.25 | $5.95 | 963,075 | |
| $6.02 | -0.43 | -6.7% | $6.42 | $6.47 | $5.98 | 1,037,128 | |
| $6.45 | +0.09 | +1.4% | $6.32 | $6.46 | $6.27 | 601,580 | |
| $6.36 | -0.08 | -1.2% | $6.52 | $6.54 | $6.25 | 819,096 | |
| $6.44 | -0.15 | -2.3% | $6.73 | $6.73 | $6.43 | 3,776,734 | |
| $6.59 | -0.14 | -2.1% | $6.84 | $6.88 | $6.46 | 916,382 | |
| $6.73 | -0.19 | -2.7% | $6.92 | $7.01 | $6.59 | 1,294,176 | |
| $6.92 | -0.09 | -1.3% | $7.11 | $7.11 | $6.605 | 712,285 | |
| $7.01 | +0.015 | +0.2% | $7.14 | $7.16 | $6.94 | 467,415 | |
| $6.995 | +0.005 | +0.1% | $7.08 | $7.08 | $6.91 | 830,854 | |
| $6.99 | -0.21 | -2.9% | $7.14 | $7.195 | $6.93 | 785,541 | |
| $7.20 | -0.16 | -2.2% | $7.34 | $7.39 | $7.16 | 465,897 | |
| $7.36 | -0.20 | -2.6% | $7.48 | $7.56 | $7.28 | 507,752 | |
| $7.56 | +0.19 | +2.6% | $7.30 | $7.57 | $7.30 | 456,395 | |
| $7.37 | -0.13 | -1.7% | $7.58 | $7.635 | $7.26 | 875,874 | |
| $7.50 | +0.07 | +0.9% | $7.46 | $7.67 | $7.00 | 495,494 | |
| $7.43 | +0.25 | +3.5% | $7.11 | $7.515 | $7.11 | 534,540 | |
| $7.18 | -0.22 | -3.0% | $7.39 | $7.40 | $7.06 | 602,504 | |
| $7.40 | -0.30 | -3.9% | $7.66 | $7.79 | $7.36 | 441,402 | |
| $7.70 | -0.03 | -0.4% | $7.70 | $7.81 | $7.64 | 440,769 | |
| $7.73 | -0.09 | -1.2% | $7.76 | $7.78 | $7.60 | 557,598 | |
| $7.82 | -0.08 | -1.0% | $7.95 | $8.105 | $7.76 | 1,131,945 | |
| $7.90 | +0.10 | +1.3% | $7.80 | $8.00 | $7.60 | 843,826 | |
| $7.80 | +0.03 | +0.4% | $7.77 | $8.085 | $7.65 | 500,883 | |
| $7.77 | -0.02 | -0.3% | $7.70 | $7.78 | $7.415 | 643,062 |
- Ticker
- NASDAQ:AURA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · Nov 9, 2026
Corporate Update (November 2026)
Corporate update · 21 slides
Latest news
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 9, 2026
Closed $7.66 (+16.8%) on Nov 9, 2026
Aura Biosciences to Participate in Upcoming Investor Conference
Nov 3, 2026
Closed $6.65 (+6.6%) on Nov 4, 2026
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 11, 2026
Closed $8.04 (+4.4%) on Aug 11, 2026
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Jul 8, 2026
Closed $7.25 (+3.1%) on Jul 8, 2026
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Jun 1, 2026
Closed $7.19 (-3.7%) on Jun 1, 2026
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
May 20, 2026
Closed $7.47 (+1.1%) on May 20, 2026
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 19, 2026
Closed $7.47 (+1.1%) on May 20, 2026
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
May 11, 2026
Closed $7.93 (-3.2%) on May 12, 2026
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 5, 2026
Closed $8.29 (-6.9%) on May 6, 2026
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
May 4, 2026
Closed $8.35 (+19.1%) on May 4, 2026
Aura Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 76 in all · newest Nov 9, 2026 · oldest 2021
- Decks
- 31 decks · latest Nov 9, 2026
Where Aura Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AURA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AURA | BOATS | United States | USD |
Valuation
Price/book 2.5× against a median of 2.2×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $433.9M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.07
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aura Biosciences, Inc. · NASDAQ:AURA | US$715.0M | US$433.9M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.07 |
| Inventiva SA · EURONEXT:IVA | US$760.9M | US$577.3M | n/a | 117× | n/a | 11.8× | n/a | 1.1× | n/a |
| Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL | US$754.9M | US$663.4M | 2.5× | 2.3× | 8.3× | 1.7× | 106.6% | 0.0× | 1.02 |
| Obsidian Therapeutics, Inc. · NASDAQ:OBX | US$741.3M | US$530.4M | 13.0× | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE | US$738.3M | US$196.8M | n/a | 2.8× | n/a | 1.5× | −186.2% | 0.1× | 0.92 |
| Aimed Bio Inc. · KRX:0009K0 | US$726.5M | US$657.3M | 25.2× | 13.2× | 34.0× | 4.8× | 57.8% | 0.0× | n/a |
| Solid Biosciences Inc. · NASDAQ:SLDB | US$697.6M | US$368.3M | n/a | n/a | n/a | 2.0× | n/a | 0.1× | 1.85 |
| Attovia Therapeutics, Inc. · NASDAQ:ATTO | US$689.3M | US$297.2M | n/a | 220× | n/a | 1.7× | n/a | 0.0× | n/a |
| Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX | US$681.2M | US$549.9M | n/a | 14.3× | n/a | 4.2× | −161.8% | 0.3× | 1.15 |
| CARsgen Therapeutics Holdings Ltd. · HKEX:2171 | US$676.0M | US$477.2M | n/a | 25.4× | n/a | 4.1× | −77.9% | 0.1× | n/a |
| Philogen SpA · MIL:PHIL | US$672.3M | US$532.7M | 2.7× | 1.5× | n/a | 1.6× | 71.8% | 0.0× | n/a |
| Median of the others | US$712.1M | US$531.6M | 7.8× | 13.7× | 21.2× | 2.2× | −10.1% | 0.0× | 1.09 |
Forecasts
5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.60 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.50 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Natalie Holles | Chief Executive Officer and President and member of the Board |
| Jill Hopkins | Chief Medical Officer, President of Research & Development |
| Susan Abu-Absi | Chief Operating Officer |
| Amy Elazzouzi | Principal Accounting Officer, Senior Vice President of Finance and Treasurer |
| Anthony Daniels | Vice President, Therapeutic Area Head Ocular Oncology |
| Patrick Nealon | Senior Vice President, Clinical Development Operations |
| Erica Kratz | Chief Regulatory and Quality Officer |
| Julie Person | Chief People Officer |
Board
| Director | Role |
|---|---|
| David Johnson | Chairman |
| Antony Mattessich | Director |
| Giovanni Mariggi | Director |
| Jeremy Bender | Director |
| Natalie Holles | Chief Executive Officer and President and member of the Board |
| Sapna Srivastava | Director |
| Teresa Bitetti | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +16.8% |
| Q2 2026 | Aug 11, 2026 · Before open | +4.4% |
| Q1 2026 | May 7, 2026 | +1.3% |
| Q4 2025 | Mar 30, 2026 · Before open | −1.1% |
| Q3 2025 | Nov 13, 2025 · Before open | −0.7% |
| Q2 2025 | Aug 13, 2025 · Before open | +4.2% |
| Q1 2025 | May 15, 2025 | +21.4% |
| Q4 2024 | Mar 24, 2025 · After close | +1.1% |
| Q3 2024 | Nov 12, 2024 · After close | −3.0% |
| Q2 2024 | Aug 8, 2024 · Before open | +3.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +2.0% |
| Q4 2023 | Mar 12, 2024 · After close | −0.8% |
| Q3 2023 | Nov 9, 2023 · After close | +9.5% |
| Q2 2023 | Aug 9, 2023 · Before open | −6.6% |
| Q1 2023 | May 11, 2023 · After close | +0.4% |
| Q4 2022 | Mar 15, 2023 · After close | +0.3% |
| Q3 2022 | Nov 10, 2022 · Before open | +1.9% |
| Q2 2022 | Aug 11, 2022 · After close | +8.9% |
| Q1 2022 | May 12, 2022 · After close | +5.8% |
| Q4 2021 | Mar 23, 2022 · After close | +3.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 21 slides | Nov 9, 2026 |
| Corporate Update (August 2026) | Corporate update | 21 slides | Aug 11, 2026 |
| Investor Presentation (May 2026) | Investor deck | 50 slides | May 11, 2026 |
| Corporate Update (November 2025) | Corporate update | 45 slides | Nov 13, 2025 |
| Investor Presentation (August 2025) | Investor deck | 54 slides | Aug 13, 2025 |
| Investor Presentation (May 2025) | Investor deck | 51 slides | May 16, 2025 |
| Investor Presentation (March 2025) | Investor deck | 59 slides | Mar 24, 2025 |
| EAU 2025 Research Forum | Conference | 12 slides | March 2025 |
| EAU 2025 | Conference | 10 slides | March 2025 |
| Corporate Update (November 2024) | Corporate update | 43 slides | Nov 12, 2024 |
All 31 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (October 2024) | Corporate update | 41 slides | Oct 17, 2024 |
| Investor Presentation (September 2024) | Investor deck | 33 slides | Sep 12, 2024 |
| Investor Presentation (August 2024) | Investor deck | 35 slides | Aug 8, 2024 |
| Investor Presentation (June 2024) | Investor deck | 33 slides | Jun 4, 2024 |
| Technical Presentation (May 2024) | Technical | 20 slides | May 24, 2024 |
| Investor Presentation (January 2024) | Investor deck | 41 slides | Jan 8, 2024 |
| Investor Presentation (November 2023) | Investor deck | 42 slides | Nov 6, 2023 |
| AAO 2023 | Conference | 19 slides | Nov 1, 2023 |
| Investor Presentation (August 2023) | Investor deck | 34 slides | Aug 9, 2023 |
| Investor Presentation (May 2023) | Investor deck | 41 slides | May 11, 2023 |
| Investor Presentation (February 2023) | Investor deck | 41 slides | Feb 16, 2023 |
| Investor Presentation (January 2023) | Investor deck | 37 slides | Jan 6, 2023 |
| Investor Presentation (November 2022) | Investor deck | 41 slides | Nov 30, 2022 |
| Investor Presentation (October 2022) | Investor deck | 46 slides | Oct 3, 2022 |
| AAO 2022 | Conference | 13 slides | Oct 3, 2022 |
| EURETINA 2022 | Conference | 12 slides | September 2022 |
| Technical Presentation (September 2022) | Technical | 20 slides | September 2022 |
| ISOO 2022 | Conference | 38 slides | Jun 22, 2022 |
| ISOO 2022 | Conference | 11 slides | June 2022 |
| Technical Presentation (May 2022) | Technical | 12 slides | May 2022 |
| ASRS 2021 | Conference | 12 slides | October 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: US$260.3M · US$6 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), LifeSci Capital, Citizens Capital Markets Use of proceeds: $205.1 million to advance clinical programs incl. early choroidal melanoma, bel-sar registration-enabling activities and general corporate purposes | May 4, 2026 |
| Public offering of equity Closed: US$75M raised · US$4.9 a share · Warrants at US$4.9 for 60 months · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Evercore ISI (co-lead), LifeSci Capital, Citizens Capital Markets, Scotiabank Use of proceeds: Advance clinical programs in choroidal melanoma, choroid metastases, ocular surface cancers and bladder cancer, and general corporate purposes | Aug 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$14.00 a share on Oct 28, 2021.
- Price
- US$14.00 a share
- Shares offered
- 5,400,000 shares of common stock
- Offering size
- US$75.6 million
- Underwriters' option
- Up to 810,000 more shares
- Underwriters
- Cowen, SVB Leerink, Evercore ISI, BTIG · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 10, 2021 |
| Filed publicly | Oct 8, 2021 |
| Amended once | Oct 25, 2021 |
| Shares registered with an exchange | Oct 26, 2021 |
| Declared effective by the SEC | Oct 28, 2021 |
| Final prospectus, with the price | Nov 1, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 1, 2021 |
| EFFECT · Notice that a registration is effective | Oct 28, 2021 |
| S-1MEF · Registration of more shares for the same offering | Oct 28, 2021 |
| CERT · Exchange's certificate of listing | Oct 28, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 26, 2021 |
| CORRESP · Letter to the SEC | Oct 26, 2021 |
| CORRESP · Letter to the SEC | Oct 26, 2021 |
| CORRESP · Letter to the SEC | Oct 25, 2021 |
| S-1/A · Registration statement, amended | Oct 25, 2021 |
| UPLOAD · Letter from the SEC | Oct 13, 2021 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 8, 2021 |
| S-1 · Registration statement | Oct 8, 2021 |
| UPLOAD · Letter from the SEC | Sep 27, 2021 |
| DRS/A · Draft registration statement, amended | Sep 20, 2021 |
| DRSLTR · Letter to the SEC with a draft | Sep 17, 2021 |
| UPLOAD · Letter from the SEC | Sep 10, 2021 |
| DRS · Draft registration statement | Aug 10, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 1, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.22M | 1.29M | 1.18M | 835.0K | 831.0K | 509.0K | |
| Gross profit | -1.22M | -1.29M | -1.18M | -835.0K | -831.0K | -509.0K | |
| Research and development | 90.3M | 73.3M | 65.2M | 42.2M | 25.2M | 18.0M | 19.1M |
| Selling, general and administrative | 22.5M | 22.8M | 19.8M | 18.1M | 10.1M | 4.16M | 4.52M |
| Operating income | -112.8M | -96.1M | -85.0M | -60.3M | -35.3M | -22.2M | -24.1M |
| Depreciation and amortization | 1.13M | 1.22M | 1.29M | 1.18M | 831.0K | 831.0K | 509.0K |
| EBITDA | -111.7M | -94.9M | -83.7M | -59.1M | -34.4M | -21.4M | -23.6M |
| Interest expense | 850.0K | 13.0K | 3.00K | 5.00K | |||
| Income before tax | -106.1M | -86.8M | -76.3M | -58.8M | -35.3M | -22.2M | -24.2M |
| Income tax | 108.0K | 112.0K | 137.0K | 0 | 0 | 0 | 5.00K |
| Net income | -106.2M | -86.9M | -76.4M | -58.8M | -35.3M | -22.2M | -24.2M |
| Earnings per share, basic | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 | -82.06 | -0.01 |
| Earnings per share, diluted | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 | -82.06 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 59.5M | 31.7M | 41.1M | 121.6M | 149.1M | 17.4M | 32.5M |
| Short-term investments | 84.7M | 119.4M | 185.1M | 67.2M | 0 | ||
| Current assets | 149.7M | 160.6M | 231.8M | 196.7M | 153.7M | 18.5M | 33.3M |
| Property, plant and equipment | 2.62M | 3.21M | 3.15M | 5.37M | 5.25M | 3.57M | 3.63M |
| Total assets | 169.4M | 182.5M | 255.1M | 223.9M | 160.0M | 22.1M | 37.1M |
| Accounts payable | 1.55M | 2.30M | 1.79M | 2.92M | 2.40M | 611.0K | 2.33M |
| Current liabilities | 18.4M | 14.9M | 12.4M | 10.5M | 7.36M | 2.66M | 6.15M |
| Long-term debt | 49.0K | ||||||
| Total debt | 17.4M | 18.8M | 19.6M | 20.9M | 975.0K | 15.0K | 49.0K |
| Total liabilities | 32.5M | 30.5M | 29.2M | 28.4M | 7.71M | 2.74M | 6.29M |
| Shareholders' equity | 136.9M | 152.0M | 225.8M | 195.6M | 152.3M | -108.7M | 30.8M |
| Shares outstanding | 63.6M | 50.0M | 49.4M | 37.8M | 29.2M | 381.1K | 2.92B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -84.7M | -79.8M | -63.8M | -54.6M | -32.4M | -24.3M | -20.7M |
| Capital spending | -447.0K | -1.25M | -709.0K | -1.09M | -2.13M | -771.0K | -2.22M |
| Free cash flow | -85.2M | -81.1M | -64.6M | -55.7M | -34.5M | -25.1M | -22.9M |
| Cash from investing | 35.6M | 68.8M | -114.0M | -67.9M | -2.13M | -771.0K | -2.22M |
| Cash from financing | 77.2M | 1.59M | 97.3M | 95.6M | 166.3M | 10.0M | 39.7M |
| Dividends paid | -39.8M | ||||||
| Share buybacks | 87.1M | 166.3M | 0 | -13.0K | |||
| Change in cash | 28.0M | -9.39M | -80.5M | -26.8M | 131.7M | -15.1M | 16.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 1, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 21, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 18, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Aug 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 8-K · Current report | Aug 5, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jun 29, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 17, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 19, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| 8-K · Current report | May 5, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 4, 2026 | Offer document | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | May 4, 2026 | Meeting notice | SEC |
| S-3MEF | May 4, 2026 | Other filings | SEC |
| 424B5 · Prospectus | May 4, 2026 | Offer document | SEC |
| 8-K · Current report | May 4, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 20, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Oct 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 17, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 19, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | May 16, 2025 | Insider trade | SEC |
| 8-K · Current report | May 16, 2025 | Material contract | SEC |
| 424B5 · Prospectus | May 16, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | May 15, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 11, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 3, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 29, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 18, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 17, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 27, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 12, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 14, 2024 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Jun 14, 2024 | Annual report | SEC |
| 8-K · Current report | Jun 4, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 15, 2024 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Apr 15, 2024 | Meeting notice | SEC |
This page holds 200 of 388 filings. Open Filings
Cap table
Built by 6ix from Aura Biosciences, Inc.’s releases · as of Nov 4, 2026
- Common shares
- 104,074,302
- Fully diluted
- 104,074,302
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 104,074,302 | Nov 4, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$4.90 · expire about May 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 104,074,302 |
| Sep 30, 2026 | 103,950,771 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jeremy Bender Other companies: Bicara Therapeutics Inc. (Director · Since at least Jul 28, 2026); Mereo BioPharma Group plc (Non-Executive Director · Since at least Jan 1, 2024); Day One Biopharmaceuticals Inc (CHIEF EXECUTIVE OFFICER, Director · Since at least May 26, 2021); Fusion Pharmaceuticals Inc (Director · Oct 16, 2023 – Jun 4, 2024 · Past) | Director · Since at least Jul 7, 2026 |
| Sapna Srivastava Other companies: Alumis Inc. (Director · Since at least Jul 30, 2025); Nuvalent, Inc. (Director · Since at least Jun 18, 2025); Tourmaline Bio Inc. (Director · Since at least Jun 4, 2025) | Director · Since at least Jun 17, 2025 |
| David Johnson Other companies: Zentalis Pharmaceuticals, Inc. (Director · Since at least Jun 16, 2026); Dynavax Technologies Corporation (Vice President · Jun 2, 2019 – Mar 13, 2020 · Past) | Director · Since at least May 4, 2026 |
| Anthony S Gibney Other companies: InflaRx N.V. (Director · Since at least Mar 18, 2026) | See Remarks · Since at least May 13, 2025 |
| Antony Mattessich Other companies: Ocular Therapeutix, Inc. (President and CEO, Director · Jun 20, 2017 – Feb 3, 2024 · Past) | Director · Since at least Oct 28, 2021 |
| Rajesh R Parekh Other companies: Celldex Therapeutics, Inc. (Director · Dec 23, 2009 – Sep 22, 2010 · Past) | Director · Oct 28, 2021 – Jun 7, 2023 · Past |
| Amy Elazzouzi | Principal Accounting Officer, Senior Vice President of Finance and Treasurer · Since at least Oct 25, 2024 |
| Anthony Daniels | Vice President, Therapeutic Area Head Ocular Oncology · Since at least Nov 5, 2026 |
| Conor Kilroy | See Remarks · Since at least Apr 16, 2026 |
| Erica Kratz | Chief Regulatory and Quality Officer · Since at least Aug 11, 2026 |
All 19 people
| Person | Seat |
|---|---|
| Giovanni Mariggi | Director · Since at least Oct 28, 2021 |
| Janet Jill Hopkins | Chief Medical Officer · Since at least Sep 1, 2026 |
| Jill Hopkins | Chief Medical Officer, President of Research & Development · Since at least Jun 1, 2026 |
| Julie Person | Chief People Officer · Since at least Aug 11, 2026 |
| Natalie Holles | Chief Executive Officer and President and member of the Board · Since at least May 19, 2026 |
| Patrick Nealon | Senior Vice President, Clinical Development Operations · Since at least Nov 5, 2026 |
| Pinos Elisabet de los | See Remarks, Director · Since at least Oct 28, 2021 |
| Susan Abu-Absi | Chief Operating Officer · Since at least Aug 10, 2026 |
| Teresa Bitetti | Director · Since at least Apr 2, 2025 |
Log in to ask 6ix AI your own questions about Aura Biosciences, Inc.